Table 2:
Comparing risks of non-COVID-specific outcomes between sotrovimab versus molnupiravir in two cohorts.
| OpenSAFELY-UKRR cohort | SRR cohort | |||||
|---|---|---|---|---|---|---|
| Outcomes | N/events | HR (95% CI) for sotrovimab (ref = molnupiravir) | P-value | N/events | HR (95% CI) for sotrovimab (ref = molnupiravir) | P-value |
| 28-day all-cause hospitalisation/death | 2350/163 | 993/75 | ||||
| Model 1 | 0.65 (0.46–0.92) | .016 | 1.04 (0.61–1.76) | .879 | ||
| Model 2 | 0.63 (0.44–0.89) | .010 | 0.80 (0.45–1.43) | .455 | ||
| Model 3 | 0.62 (0.43–0.89) | .009 | 0.71 (0.39–1.29) | .273 | ||
| Model 4 | 0.60 (0.41–0.85) | .004 | ||||
| 28-day other-cause hospitalisation/death | 2350/130 | 993/56 | ||||
| Model 1 | 0.85 (0.56–1.29) | .441 | 1.29 (0.68–2.40) | .426 | ||
| Model 2 | 0.79 (0.52–1.21) | .276 | 0.97 (0.47–1.95) | .934 | ||
| Model 3 | 0.76 (0.49–1.16) | .205 | 0.90 (0.44–1.84) | .776 | ||
| Model 4 | 0.73 (0.48–1.12) | .151 | ||||
In the OpenSAFELY-UKRR cohort, Model 1 adjusted for age and sex; Model 2 additionally adjusted for high-risk cohort categories, KRT modality and duration; Model 3 additionally adjusted for ethnicity, IMD quintiles, vaccination status, calendar date; and Model 4 additionally adjusted for BMI category, diabetes, hypertension, chronic cardiac and respiratory diseases. In the SRR cohort, Model 1 adjusted for age and sex; Model 2 additionally adjusted for modality, PRD group and KRT duration; Model 3 additionally adjusted for SIMD, vaccination status and calendar time.